New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib

被引：20

作者：

Koelblinger, Peter ^{[1
]}

Lang, Roland ^{[1
]}

机构：

[1] Paracelsus Med Univ, Dept Dermatol, Muellner Hauptrasse 48, A-5020 Salzburg, Austria

来源：

ONCOTARGETS AND THERAPY | 2018年 / 11卷

关键词：

basal cell carcinoma; treatment; PTCH1; hedgehog inhibitor; HEDGEHOG PATHWAY INHIBITOR; AMINOLEVULINATE PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED-TRIAL; IMIQUIMOD 5-PERCENT CREAM; DOUBLE-BLIND; RECURRENCE RATES; OPEN-LABEL; FOLLOW-UP; SURGICAL EXCISION; ADVERSE EVENTS;

D O I：

10.2147/OTT.S135650

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide. Although most BCCs can be treated by relatively simple surgical or nonsurgical methods, some patients with BCC may eventually develop advanced disease which can either be locally destructive or even include metastatic spread. The present review summarizes the current literature on the treatment of both early and advanced BCC with a focus on the hedgehog inhibitor vismodegib which has become an integral part of the management of patients with advanced BCC since its regulatory approval in 2012.

引用

页码：8327 / 8340

页数：14

共 125 条

[1] New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases [J].

Aasi, Sumaira ;

Silkiss, Rona ;

Tang, Jean Y. ;

Wysong, Ashley ;

Liu, Andy ;

Epstein, Ervin ;

Oro, Anthony E. ;

Chang, Anne Lynn S. .

JAMA DERMATOLOGY, 2013, 149 (02) :242-243

[2] Persistent alopecia induced by vismodegib [J].

Alkeraye, S. ;

Maire, C. ;

Desmedt, E. ;

Templier, C. ;

Mortier, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (06) :1671-1672

[3] Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps [J].

Ally, Mina S. ;

Tang, Jean Y. ;

Lindgren, Joselyn ;

Acosta-Raphael, Maria ;

Rezaee, Melika ;

Chanana, Anita M. ;

Epstein, Ervin H., Jr. .

JAMA DERMATOLOGY, 2015, 151 (10) :1132-1134

[4]

[Anonymous], 2018, NCCN Clinical Practice Guidelines in Oncology, DOI DOI 10.1016/B978-0-323-35762-3.00092-5

[5] Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012 [J].

Asgari, Maryam M. ;

Moffet, Howard H. ;

Ray, G. Thomas ;

Quesenberry, Charles P. .

JAMA DERMATOLOGY, 2015, 151 (09) :976-981

[6] Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety [J].

Ash, Mark M. ;

Jolly, Puneet S. .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 2015, 54 (03) :370-374

[7] Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma [J].

Atwood, Scott X. ;

Sarin, Kavita Y. ;

Whitson, Ramon J. ;

Li, Jiang R. ;

Kim, Geurim ;

Rezaee, Melika ;

Ally, Mina S. ;

Kim, Jinah ;

Yao, Catherine ;

Chang, Anne Lynn S. ;

Oro, Anthony E. ;

Tang, Jean Y. .

CANCER CELL, 2015, 27 (03) :342-353

[8] Basal cell carcinoma of the face: Surgery or radiotherapy? Results of a randomized study [J].

Avril, MF ;

Auperin, A ;

Margulis, A ;

Gerbaulet, A ;

Duvillard, P ;

Benhamou, E ;

Guillaume, JC ;

Chalon, R ;

Petit, JY ;

SanchoGarnier, H ;

Prade, M ;

Bouzy, J ;

Chassagne, D .

BRITISH JOURNAL OF CANCER, 1997, 76 (01) :100-106

[9] U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma [J].

Axelson, Michael ;

Liu, Ke ;

Jiang, Xiaoping ;

He, Kun ;

Wang, Jian ;

Zhao, Hong ;

Kufrin, Dubravka ;

Palmby, Todd ;

Dong, Zedong ;

Russell, Anne Marie ;

Miksinski, Sarah ;

Keegan, Patricia ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2013, 19 (09) :2289-2293

[10] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial [J].

Basset-Seguin, N. ;

Hauschild, A. ;

Kunstfeld, R. ;

Grob, J. ;

Dreno, B. ;

Mortier, L. ;

Ascierto, P. A. ;

Licitra, L. ;

Dutriaux, C. ;

Thomas, L. ;

Meyer, N. ;

Guillot, B. ;

Dummer, R. ;

Arenberger, P. ;

Fife, K. ;

Raimundo, A. ;

Dika, E. ;

Dimier, N. ;

Fittipaldo, A. ;

Xynos, I. ;

Hansson, J. .

EUROPEAN JOURNAL OF CANCER, 2017, 86 :334-348

← 1 2 3 4 5 6 7 8 9 10 →